

Ennio Giulio Favalli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7885309/ennio-giulio-favalli-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

3,351
citations

32
h-index

54
g-index

140
ext. papers

4,031
ext. citations

5.8
avg. IF

6.13
L-index

#	Paper	IF	Citations
110	Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 21	5.7	6
109	The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.. <i>Frontiers in Medicine</i> , 2022 , 9, 850858	4.9	0
108	Are patients with systemic lupus erythematosus at increased risk for COVID-19?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e25	2.4	27
107	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 561-571	5.1	3
106	Secukinumab in HLA-B27 associated uveitis. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 388-389	2.4	0
105	Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1243-1244	2.4	4
104	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 661-670	3.8	1
103	What is the true incidence of COVID-19 in patients with rheumatic diseases?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e18	2.4	73
102	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e75	2.4	13
101	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021 , 88, 105062	2.9	5
100	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021 , 116, 102545	15.5	18
99	An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. <i>Frontiers in Medicine</i> , 2021 , 8, 711875	4.9	0
98	Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. <i>Arthritis Care and Research</i> , 2021 ,	4.7	4
97	Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
96	Dr. Favalli, reply. <i>Journal of Rheumatology</i> , 2020 , 47, 1592	4.1	4
95	Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1600-1606	9.5	68
94	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20906040	2.8	21

93	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. <i>Autoimmunity Reviews</i> , 2020 , 19, 102523	3.6	241
92	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020 , 19, 102509	13.6	8
91	Managing patients with rheumatic conditions during the covid-19 pandemic. <i>BMJ, The</i> , 2020 , 369, m1633	3.9	4
90	Tofacitinib's infectious profile: concerns for clinical practice. <i>Lancet Rheumatology, The</i> , 2020 , 2, e65-e67	14.2	6
89	Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	11
88	Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. <i>Journal of Rheumatology</i> , 2020 , 47, 1296	4.1	54
87	Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days. <i>Dermatologic Therapy</i> , 2020 , 33, e13415	2.2	10
86	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 290	5.7	17
85	The Giants (biologics) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102421	13.6	12
84	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020 , 6,	5.9	5
83	GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?. <i>Lancet Rheumatology, The</i> , 2020 , 2, e448-e449	14.2	5
82	Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020 , 7, 473-516	4.4	30
81	Is there really room for anti-rheumatic drugs in the treatment of COVID-19?. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 412-413	1.9	0
80	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020 , 35, 163-169	0.9	0
79	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. <i>Rheumatology International</i> , 2020 , 40, 263-272	3.6	3
78	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1012-1013	25.5	137
77	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. <i>Pediatric Rheumatology</i> , 2020 , 18, 35	3.5	26
76	Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 19-26	2.2	3

75	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019 , 79, 1741-1755	12.1	31
74	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 573-581	5.9	19
73	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1313-1322	5.1	6
72	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019 , 8, 212595	5.2	28
71	SAT0375 MILD COGNITIVE IMPAIRMENT IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS 2019 ,		1
70	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. <i>BioMed Research International</i> , 2019 , 2019, 6107217	3	10
69	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019 , 56, 333-345	3.5	49
68	Incidence du cancer chez les patients atteints de spondyloarthrite traitée par anti-TNF. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 75-80	0.1	
67	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 57-70	4.4	71
66	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 422-430	2.3	17
65	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics Register GISEA. <i>Clinical Rheumatology</i> , 2018 , 37, 315-321	3.9	27
64	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018 , 28, 542-549	3.3	7
63	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018 , 85, 455-459	2.9	11
62	Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study". <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, e119-e120	4.5	1
61	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1421-1429	4.4	10
60	The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2018 , 148, w14656	3.1	7
59	Vitamin D and Spondyloarthritis: Review of the Literature. <i>Open Rheumatology Journal</i> , 2018 , 12, 214-225.	2.2	3
58	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018 , 2018, 9460187	3	9

57	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018 , 57, vii42-vii53	3.9	18
56	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018 , 17, 1251-1258	13.6	1
55	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018 , 9, 275-284	2.9	7
54	Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 479-485	2.2	2
53	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017 , 36, 753-761	3.9	17
52	The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. <i>Journal of Rheumatology</i> , 2017 , 44, 279-285	4.1	51
51	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017 , 36, 1747-1755	3.9	23
50	Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. <i>Journal of Rheumatology</i> , 2017 , 44, 262-263	4.1	3
49	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 183-192	5.3	53
48	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017 , 16, 1185-1195	13.6	51
47	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1593-1603	4.4	64
46	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The management of these diseases in the clinical setting. <i>Journal of Rheumatology</i> , 2017 , 44, 264-265	13.6	84
45	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017 , 69, 867-874	4.7	23
44	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1969-1978	4.4	10
43	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 211-223	4.4	14
42	Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 9-17	1.7	16
41	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 660-665	2.2	5
40	Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 804-809	2.2	17

39	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016 , 35, 2649-2656 ¹⁴	3.9	14
38	Biomarkers in psoriatic arthritis: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 651-60	5.1	26
37	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 519-32	5.3	41
36	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016 , 68, 432-9	4.7	57
35	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016 , 44, 113-118	1.4	11
34	Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1155-64	9.5	76
33	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e5	2.4	8
32	Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. <i>Immunologic Research</i> , 2015 , 61, 24-30	4.3	42
31	Structural integrity versus radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , 2015 , 1, e000064.9	4.9	7
30	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12	2.9	15
29	Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. <i>Clinica Chimica Acta</i> , 2014 , 437, 161-7	6.2	10
28	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014 , 53, 1664-8	3.9	60
27	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1102-8	13.6	55
26	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 730-7	5.3	8
25	Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modérés ou élevés. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014 , 81, 54-57	0.1	
24	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28'scores. <i>Joint Bone Spine</i> , 2014 , 81, 37-40	2.9	19
23	Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. <i>Drug Development Research</i> , 2014 , 75 Suppl 1, S38-41	5.1	28
22	Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. <i>BioMed Research International</i> , 2014 , 2014, 831603	3	18

21	Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. <i>BioMed Research International</i> , 2014 , 2014, 416892	3	7
20	Ultrasonography in the diagnosis and management of patients with inflammatory arthritides. <i>European Journal of Internal Medicine</i> , 2014 , 25, 103-11	3.9	10
19	Novel mechanisms of action of the biologicals in rheumatic diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2014 , 47, 6-16	12.3	20
18	Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013 , 65, 94-100	4.7	137
17	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012 , 12, 225-9	13.6	125
16	Damage progression in rheumatoid arthritis: the role of biologic agents. <i>Arthritis Research and Therapy</i> , 2012 , 14,	5.7	78
15	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 213-23	3.8	9
14	Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. <i>Autoimmunity Reviews</i> , 2011 , 10, 460-3	13.6	17
13	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S15-27	2.2	30
12	Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). <i>Rheumatology</i> , 2010 , 49, 289-94	3.9	63
11	Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010 , 38, 90-6	12.3	52
10	Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010 , 9, 175-80	13.6	71
9	Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010 , 9, 465-9	13.6	35
8	TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 837-46	6.5	110
7	Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. <i>Autoimmunity Reviews</i> , 2009 , 8, 260-5	13.6	32
6	Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009 , 8, 266-73	13.6	134
5	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. <i>Autoimmunity Reviews</i> , 2009 , 8, 274-80	13.6	89
4	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009 , 8, 431-7	13.6	47

- 3 Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. *Journal of Autoimmunity*, **2008**, 31, 175-9 15.5 87
- 2 Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. *Arthritis and Rheumatism*, **2004**, 51, 301-2 21
- 1 Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. *Lupus*, **2002**, 11, 753-5 2.6 67